Macrolides from rare actinomycetes: Structures and bioactivities

Al-Fadhli, Ammar A.; Threadgill, Michael D.; Mohammed, Faez; Sibley, Paul K.; Al-Ariqi, Wadie; Parveen, Ifat

doi:10.1016/j.ijantimicag.2022.106523

Cited by 18 publications

(11 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Macrolides are antibiotics produced by gram-positive Actinomycetes and were discovered in the 1950s. 69 A large number of macrolide antibiotics are now available for standard medical care and specifically as an alternative therapy for penicillin-allergic patients. 70…”

Section: Resultsmentioning

confidence: 99%

Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis

et al. 2022

View full text Add to dashboard Cite

Approximately 40% of treatments of chronic and recurrent osteomyelitis fail in part due to bacterial persistence. Staphylococcus aureus, the predominant pathogen in human osteomyelitis, is known to persist by phenotypic adaptation as small-colony variants (SCVs) and by formation of intracellular reservoirs, including those in major bone cell types, reducing susceptibility to antibiotics. Intracellular infections with S. aureus are difficult to treat; however, there are no evidence-based clinical guidelines addressing these infections in osteomyelitis. We conducted a systematic review of the literature to determine the demonstrated efficacy of all antibiotics against intracellular S. aureus relevant to osteomyelitis, including protein biosynthesis inhibitors (lincosamides, streptogramins, macrolides, oxazolidines, tetracyclines, fusidic acid, and aminoglycosides), enzyme inhibitors (fluoroquinolones and ansamycines), and cell wall inhibitors (beta-lactam inhibitors, glycopeptides, fosfomycin, and lipopeptides). The PubMed and Embase databases were screened for articles related to intracellular S. aureus infections that compared the effectiveness of multiple antibiotics or a single antibiotic together with another treatment, which resulted in 34 full-text articles fitting the inclusion criteria. The combined findings of these studies were largely inconclusive, most likely due to the plethora of methodologies utilized. Therefore, the reported findings in the context of the models employed and possible solutions for improved understanding are explored here. While rifampicin, oritavancin, linezolid, moxifloxacin and oxacillin were identified as the most effective potential intracellular treatments, the scientific evidence for these is still relatively weak. We advocate for more standardized research on determining the intracellular effectiveness of antibiotics in S. aureus osteomyelitis to improve treatments and patient outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Some of these genera are well known as producers of relevant antibiotics with clinical applications, including rifamycins from Amycolatopsis mediterranei , vancomycin from Amycolatopsis orientalis , erythromycin from Saccharopolyspora erythraea , teicoplanin from Actinoplanes teichomyceticus , and gentamicin from Micromonospora purpurea [ 17 ]. The importance of minor genera of actinomycetes has been corroborated by the discovery of several novel compounds in the last years [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ], such as kongjuemycins [ 23 ], catellatolactams [ 24 ], and persicamidines [ 25 ], so these genera represent an untapped resource of potential new bioactive natural products [ 17 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Complete Genome Sequence Analysis of Kribbella sp. CA-293567 and Identification of the Kribbellichelins A & B and Sandramycin Biosynthetic Gene Clusters

et al. 2023

View full text Add to dashboard Cite

Minor genera actinomycetes are considered a promising source of new secondary metabolites. The strain Kribbella sp. CA-293567 produces sandramycin and kribbellichelins A & B In this work, we describe the complete genome sequencing of this strain and the in silico identification of biosynthetic gene clusters (BGCs), focusing on the pathways encoding sandramycin and kribbellichelins A–B. We also present a comparative analysis of the biosynthetic potential of 38 publicly available genomes from Kribbella strains.

show abstract

“…Microorganisms are an inexhaustible source of new bioactive molecules [ 5 ], with actinomycetes having produced nearly 10,000 antibiotics to date [ 6 ]. However, finding new compounds from traditional sources has become less likely in recent years [ 7 ], leading scientists to explore alternative microbial sources such as rare actinomycetes, insect-associated actinomycetes, and underrepresented taxa [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Antifungal activity of compounds from Gordonia sp. WA8-44 isolated from the gut of Periplaneta americana and molecular docking studies

Liu¹,

Li²,

Liu³

et al. 2023

Heliyon

View full text Add to dashboard Cite

Macrolides from rare actinomycetes: Structures and bioactivities

Cited by 18 publications

References 101 publications

Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis

Can intracellular Staphylococcus aureus in osteomyelitis be treated using current antibiotics? A systematic review and narrative synthesis

Complete Genome Sequence Analysis of Kribbella sp. CA-293567 and Identification of the Kribbellichelins A & B and Sandramycin Biosynthetic Gene Clusters

Antifungal activity of compounds from Gordonia sp. WA8-44 isolated from the gut of Periplaneta americana and molecular docking studies

Contact Info

Product

Resources

About